CLGN CollPlant Biotechnologies Ltd

  1. Stocks
  2. Healthcare
  3. NASDAQ: CLGN

Price (delayed)

$4.04

Market cap

$5.83M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$10.3

Enterprise value

$4.21M

Sign up for free to view scoring metrics ?
Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 5
Highlights
The debt has contracted by 7% from the previous quarter and by 7% YoY
The company's EPS rose by 16% YoY but it fell by 10% QoQ
The company's net income fell by 14% QoQ but it rose by 5% YoY
CLGN's gross profit has plunged by 148% YoY and by 137% from the previous quarter
The revenue has plunged by 84% YoY and by 84% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.collplant.com
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of CLGN

CLGN stock price

How has the CollPlant Biotechnologies stock price performed over time
Intraday
4.94%
1 week
16.09%
1 month
29.49%
1 year
-84.16%
YTD
-71.14%
QTD
15.76%

Financial performance

How have CollPlant Biotechnologies's revenue and profit performed over time
Revenue
$389,000
Gross profit
-$574,000
Operating income
-$12.95M
Net income
-$13.13M
Gross margin
-147.6%
Net margin
-3,376.3%
CLGN's gross profit has plunged by 148% YoY and by 137% from the previous quarter
The revenue has plunged by 84% YoY and by 84% from the previous quarter
The company's net income fell by 14% QoQ but it rose by 5% YoY
CollPlant Biotechnologies's operating income has decreased by 13% QoQ but it has increased by 11% YoY

Price vs fundamentals

How does CLGN's price correlate with its fundamentals

Growth

What is CollPlant Biotechnologies's growth rate over time

Valuation

What is CollPlant Biotechnologies stock price valuation
P/E
N/A
P/B
1.06
P/S
14.28
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
10.83
The company's EPS rose by 16% YoY but it fell by 10% QoQ
The P/B is 63% less than the 5-year quarterly average of 2.7 and 58% less than the last 4 quarters average of 2.4
The equity has plunged by 61% YoY and by 20% from the previous quarter
The revenue has plunged by 84% YoY and by 84% from the previous quarter
CLGN's price to sales (P/S) is 78% lower than its 5-year quarterly average of 61.9 but 12% higher than its last 4 quarters average of 12.1

Efficiency

How efficient is CollPlant Biotechnologies business performance
CollPlant Biotechnologies's ROE has plunged by 84% YoY and by 40% from the previous quarter
CLGN's ROA has dropped by 56% year-on-year and by 32% since the previous quarter
The ROIC has contracted by 22% from the previous quarter and by 20% YoY

Dividends

What is CLGN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CLGN.

Financial health

How did CollPlant Biotechnologies financials performed over time
CLGN's total assets is 114% greater than its total liabilities
The quick ratio has plunged by 56% YoY and by 16% from the previous quarter
The current ratio has declined by 49% year-on-year and by 10% since the previous quarter
The debt is 46% less than the equity
CollPlant Biotechnologies's debt to equity has surged by 135% YoY and by 15% QoQ
The equity has plunged by 61% YoY and by 20% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.